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Abstract 
Background 
Studies have documented associations between clinical measures and the initiation and 
progression of periodontal disease in pregnant women. However, no studies have 
examined potential prognostic factors associated with gain in clinical attachment level, 
decreased probing depths and decreased bleeding on probing in response to scaling and 
root planing in pregnant women with chronic periodontitis. Hence, the goal of the present 
study is to determine if certain baseline clinical, serological parameters and patient 
characteristics can predict initial response to non-surgical periodontal therapy in pregnant 
women with chronic periodontitis.  
Methods 
We studied associations between periodontal treatment response and a variety of baseline 
demographic, clinical and serological characteristics and measures. The response to 
periodontal treatment was defined as full-mouth mean change from baseline to 29-32 
weeks gestation using three periodontal measures: Clinical attachment level (CAL), 
probing depth (PD) and percentage of sites with bleeding on probing (BOP). The 
association between each of the response measures and the predictors were examined 
using simple and multiple linear regression in univariate and multivariate analyses. 
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Results 
Baseline endotoxin (β = -0.74 mm) and CRP (β = 0.22 mm) levels were significantly 
associated with gain in CAL. We also found significant interaction between baseline PD 
and anti- T. denticola antibodies as well as between CRP and anti- T. denticola antibodies 
in relationship with gain in CAL. Anti- P. intermedia antibodies were negatively 
associated with decreased BOP. Interaction of anti-C. rectus antibodies and PGE2 levels 
with clinical center showed a significant association with decreased PD.  
Conclusion 
The findings of the present study suggest that baseline patient characteristics such as 
race; serum measures such as CRP, endotoxins and antibodies to T. denticola; and 
periodontal measures such as PD, play a significant role in predicting the gain in CAL 
after non-surgical periodontal treatment in pregnant women with chronic periodontitis. 
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INTRODUCTION 
 
The periodontal diseases are a group of infectious diseases that vary by clinical 
presentation and pathogenic mechanisms.1 Numerous studies have reported that 
pregnancy can adversely affect a woman's periodontal health.2-4  The prevalence of 
severe periodontitis during pregnancy ranges from five percent to 20 percent 5-7 with 
about 25 percent of women showing a worsening of their periodontal condition during 
pregnancy.5, 6 
Proper periodontal diagnosis and successful treatment is predicated on a thorough 
understanding of the complex pathobiology of periodontal disease.1 By better 
understanding disease processes, clinicians may also be better able to predict an 
individual's periodontal treatment response, which also enables the patient to make an 
informed decision about accepting treatment recommendations. Clinicians can use this 
information to determine the most effective treatment modality for the patient and to 
develop restorative recommendations.8, 9 
Although a patient's course of treatment is often determined solely by their baseline 
clinical status, it is better for clinicians to consider related factors that could affect 
periodontal treatment response.1 Though the efficacy of non-surgical periodontal therapy 
has been demonstrated through many studies,10-13 relatively few studies have identified 
prognostic factors related to the periodontal treatment response, and accurate 
prognostication remains a formidable challenge for dental professionals.14 Studies 
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assessing prognosis of a tooth after periodontal treatment have examined various 
periodontal parameters such as probing depth, bleeding on probing and clinical 
attachment loss.8, 15 Others have reported associations between tooth loss following 
periodontal treatment and selected clinical, radiographic measures and patient 
characteristics such as age, gender, systemic illnesses, smoking history, and genetic 
factors.9, 16 
Studies have documented associations between clinical measures and the initiation and 
progression of periodontal disease in pregnant women.3, 5 However, no studies have 
examined potential prognostic factors associated with gain in clinical attachment level, 
decreased probing depths and decreased bleeding on probing in response to scaling and 
root planing in pregnant women with chronic periodontitis. Knowledge of such 
prognostic factors may enable clinicians to target pregnant women who are most likely to 
respond favorably to this treatment during their pregnancy. Therefore, we carried out a 
secondary analysis of data from the Obstetrics and Periodontal Therapy (OPT) trial17 to 
determine the possible predictive role of selected baseline patient characteristics, clinical 
parameters and serological measures on the response to non-surgical treatment (scaling 
and root planing plus monthly tooth polishing) in pregnant women with chronic 
periodontitis. 
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METHODS 
The present study was a secondary analysis of data collected during the OPT Trial, which 
was a multicenter, single-blind, randomized controlled trial conducted to assess whether 
non-surgical periodontal therapy in pregnant women with periodontitis affects gestational 
age at delivery. The trial's design and methodology has been previously described.17 
Briefly, the OPT trial enrolled 823 pregnant women, between 13 to16 weeks and 6 days 
of gestation, with periodontitis.  Participants were enrolled between March 2003 and June 
2005 at four clinical centers (University of Kentucky (KY); Hennepin County Medical 
Center (MN); Harlem Hospital (NY); and the University of Mississippi Medical Center 
(MS)). They were randomly assigned to receive scaling and root planing before 21 weeks 
of gestation followed by monthly periodontal maintenance visits (Treatment Group), or 
delayed (post-partum) periodontal treatment (Control Group). The present analysis study 
was limited to the 413 women randomized to the treatment group.  
Full-mouth periodontal assessments were made at baseline (13 to16 weeks and 6 days of 
gestation) and again at 21-24 weeks and 29-32 weeks of gestation. Trained and calibrated 
masked examiners (nine across four clinical centers) measured the gingival index (GI),18 
probing depth, the distance from the cemento-enamel junction to the gingival margin 
(CEJ-GM) and bleeding on probing from six sites (mesiobuccal, mid- or direct buccal, 
distobuccal, distolingual, mid- or direct lingual, and mesiolingual) on all teeth, excluding 
third molars. Clinical attachment level was computed from the PD and CEJ-GM 
measures. Plaque and calculus were assessed on the six Ramfjord index teeth (the 
maxillary right first molar, maxillary left central incisor, maxillary left first bicuspid, 
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mandibular left first molar , mandibular right central incisor, and mandibular right first 
bicuspid).  
Serum and microbiologic samples were collected and more information about serum 
sampling and microbiological analysis can be found elsewhere.19, 20 Briefly, at baseline 
and again at 29 to 32 weeks’ gestation, a trained examiner obtained a pooled sub-gingival 
plaque sample from each participant. Microbiologic samples were taken from the four 
deepest sites in the dentition that bled on probing using sterile curets. Dental plaque 
samples from the four tooth sites were placed into a single labeled micro-centrifuge tube 
containing 1ml sterile phosphate-buffered saline and immediately frozen at -70°C. 
Samples stored at the clinical centers were periodically shipped on dry ice via overnight 
courier to the coordinating center at the University of Minnesota. Serum was isolated 
from whole blood samples obtained at baseline, prior to periodontal care, and at 29 to 32 
weeks of gestation.  Serum samples were stored at -80°C and shipped in batches on dry 
ice via overnight courier to a central laboratory for further analysis. C-reactive protein 
(CRP) was quantitated using a capture enzyme-linked immunosorbent assay (ELISA). 
[24, 25] Interleukin (IL)-1ß, IL-6, IL-8, prostaglandin-E2 (PGE2) and tumor necrosis 
factor-alpha (TNF-α) were quantitated by ELISA using mouse monoclonal antibodies. 
Matrix metalloproteinase-9 (MMP-9) was assayed using a commercial ELISA kit. Serum 
IgG antibody levels to seven periodontal bacteria (Aggregatibacter 
actinomycetemcomitans, Campylobacter rectus, Fusobacterium nucleatum, 
Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola, and Tannerella 
5 
  
forsythia) were assayed using ELISA methods. Finally, endotoxin activity was analyzed 
using a commercial kit.  
We studied associations between  periodontal treatment response and a variety of 
baseline demographic, clinical and serological characteristics and measures such as age, 
clinical center, race, body-mass index (BMI), education, diabetes status and smoking 
status, full-mouth average clinical attachment level (CAL), full-mouth average probing 
depth (PD), percentage of sites with bleeding on probing (BOP), plaque index score (PI) 
[20], levels of CRP, IL-1β, IL-6, IL-8, PGE2, TNF-α, MMP-9, endotoxin, fibrinogen and 
antibody counts for the seven bacterial species. We excluded IL-1β, IL-6, IL-8 and TNF-
α from the analyses because these cytokines were undetectable in greater than 90% of the 
serum samples (Appendix Table 7). 
We summarized the response to periodontal treatment as full-mouth mean change from 
baseline to 29-32 weeks gestation using three periodontal measures: CAL, PD and 
percentage of sites with BOP. When data from the 29-32 week exam were not available, 
data from the 21-24 week exam were substituted. The primary outcome was gain in CAL; 
change in full-mouth PD and BOP defined as decreased PD and decreased BOP were 
considered as secondary outcomes.  
Statistical Analysis 
We used SAS (Version 9.3, SAS Institute, Cary, N.C.) to calculate descriptive statistics 
for all the baseline variables. Checks on the normality assumptions were assessed and log 
(base 10) of all serological measurements, except Endotoxin, were analyzed. We 
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computed Pearson correlation coefficients (r) between the baseline periodontal measures 
and between changes in CAL, PD and BOP.  To avoid spurious associations, we did not 
explore relationships between a baseline measure and change in the same measure (e.g., 
baseline CAL and gain in CAL).21 Next, the association between each of the response 
measures and the predictors were examined using simple and multiple linear regression in 
univariate and multivariate analyses, respectively. We included in the multivariate 
models only those predictors that were associated with the outcome variable in univariate 
analysis (p≤0.10) as well as those which showed significant interactions (p≤0.05).  Next, 
we reduced the multiple regression models by dropping non-significant predictors 
starting with those with a p-value ≥ 0.50, then by excluding those with a p-value ≥ 0.25 
followed by those with a p-value ≥ 0.05. We examined the association between the 
outcome and a categorical predictor using SAS’s Least Squares Means method (LS-
Means), defined as a linear combination (sum) of the estimated effects (e.g. means) from 
a linear model which are adjusted for the average value of the specified covariate(s).22, 23  
We also screened for two-way interactions for all baseline predictors and included the 
significant interactions (p≤0.05) in the adjusted analyses. For the interpretation of the 
interaction term including two continuous measures, we used the specific formula 
[Outcome=Slope of predictor 1 + (Slope of interaction term* Average of predictor 2)] to 
calculate the actual response based on these interaction terms. To examine the effect of 
clinical center on the association, separate analyses with and without the variable clinical 
center were conducted for the primary and secondary outcomes. 
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RESULTS 
Of the 413 women in the treatment group, 60 participants did not have follow-up 
periodontal measures at 21-24 weeks or at 29-32 weeks of gestation. Additionally, 
baseline serum data were available for 401 of the 413 women. Table 1 summarizes 
baseline characteristics of study participants. The mean age of participants was 26 years 
with a greater proportion of Black participants (46%) as compared to other races. More 
than half of the participants had 9-12 years of education (57.4%). The MN clinical center 
enrolled a slightly higher proportion of participants (29.6%) as compared to the other 
clinical centers. 
 
 
Table 1: Baseline Characteristics of Study Participants 
Characteristics Study Group 
(n=413)* 
Age (Yrs) 26.1 ± 5.6 
BMI (Kg/m2) 27.8 ± 7.4 
Race - No. (%)  
     Black 190 (46.0) 
     Native American 132 (31.9) 
     White 116 (28.1) 
Ethnicity - No. (%)  
     Hispanic 170 (50.3) 
Education - No. (%)  
     ≤ 8 years 78 (18.9) 
     9-12 years 237 (57.4) 
     > 12 years 98 (23.7) 
Diabetics - No. (%)                                               16  (3.8) 
Smokers - No. (%)     49 (12.2) 
Clinical Center - No. (%)  
      MN 130 (29.6)  
      KY 123 (28) 
      MS 99 (22.6) 
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      NY 86 (19.6)  
Periodontal measures  
     Tooth sites with bleeding on probing (%) 69.7 ± 17.4 
     Full-mouth mean probing depth (mm) 2.89 ± 0.6 
     Full-mouth mean clinical attachment level (mm) 1.45 ± 0.7 
     Full-mouth mean plaque index score 1.24 ± 0.5 
Serum measures   
     ¶Anti-A. actinomycetemcomitans antibodies 8.10 ± 8.2 
     Anti-C. rectus antibodies 5.50 ± 3.4 
     Anti-F. nucleatum antibodies 3.14 ± 2.2 
     Anti-P. gingivalis antibodies 17.02 ± 17.3 
     Anti-P. intermedia antibodies 5.90 ± 3.9 
     Anti-T. denticola antibodies 4.64 ± 3.1 
     Anti- T. forsythus antibodies 7.26 ± 5.1 
     CRP (ng/ml) 9.53 ± 10.9 
     IL-1β (pg/ml) 2.97 ± 4.7 
     IL-6 (pg/ml) 20.0 ± 98.4 
     IL-8 (pg/ml) 2.62 ± 3.6 
     PGE2 (pg/ml) 311.4 ± 324.4 
     TNF-α (pg/ml) 2.73 ± 3.1 
     MMP-9 (µg/ml) 0.70 ± 0.5 
     Endotoxin (EU/ml) 1.79 ± 1.1 
     Fibrinogen (pg/ml) 20.23 ± 13.3 
*± values represent standard deviation. 
¶ the antibody levels to seven periodontal bacteria are expressed as ng or µg/ml of IgG reactivity 
 
In order to better understand associations between clinical center and the outcomes, we 
explored differences in the baseline characteristics according to clinical centers 
(Appendix Table 1). Except for CRP levels, significant differences were noted for all 
baseline characteristics between clinical centers. Variables that showed a significant 
association (p<0.05) with the primary outcome i.e. gain in CAL in an univariate analysis 
are presented in the appendix (Appendix Table 2). 
Table 2 shows the results from a multivariate analysis for the primary outcome including 
the variable clinical center in the model. Participants from the KY clinical center showed 
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a greater gain in CAL (0.54 mm) as compared to other clinical centers. Baseline 
endotoxin and CRP levels were significantly associated with gain in CAL. Endotoxin 
levels showed a strong negative association with gain in CAL (β = -0.74 mm), indicating 
that per unit increase in endotoxin levels at baseline was associated with a 0.74 mm loss 
of clinical attachment 29-32 weeks. We also found significant interactions between 
baseline PD and anti- T. denticola antibodies and between CRP and anti- T. denticola 
antibodies in relationship with the primary outcome. This means that the association 
between baseline PD and gain in CAL was affected by anti- T. denticola antibodies or 
vice versa. Specifically, we found that there was 0.9 mm gain in CAL for each 1 mm 
increase in baseline PD when anti- T. denticola antibodies are at an average level, i.e., 4.6 
µg/ml. However, when anti- T. denticola antibodies were 7.7 µg/ml (i.e., 1 SD larger than 
the sample average), there was 1.31 mm gain in CAL for each 1 mm increase in baseline 
PD. Similarly, interaction of CRP and anti- T. denticola antibodies showed 7.8 mm gain 
in CAL for each 1 unit increase in CRP when anti- T. denticola antibodies were at the 
sample average. 
When clinical center was not included in the adjusted regression model, race was 
significantly associated with gain in CAL (Table 3). Native American participants 
showed higher gain in CAL as compared to Black and Whites. Also, baseline PI score 
and endotoxin levels were negatively associated with gain in CAL. The interaction of 
baseline PD and race was significant, indicating that the association between baseline PD 
and gain in CAL depends on an individual's race. Native American participants showed 
0.62 mm gain in CAL when baseline PD was 2.89 mm, the sample average. 
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Table 2: Multivariate regression analyses for Gain in Clinical attachment Level 
including Clinical Center 
Variables          Adjusted β ± SE* P value 
Clinical Center†   
   MN 0.33 ± 0.04 <0.0001 
   KY 0.54 ± 0.04 <0.0001 
   MS 0.09 ± 0.05   0.0560 
   NY 0.18 ± 0.05    0.0004 
Baseline PD 0.30 ± 0.05 <0.0001 
CRP           0.22 ± 0.10   0.0247 
Endotoxin 
Anti-T. denticola antibodies                                                 
         -0.74 ± 0.21 
-0.28 ± 0.05              
  0.0004 
  0.6000 
Baseline PD x Anti-T. denticola 
antibodies 
0.13 ± 0.05   0.0126 
CRP x Anti-T. denticola antibodies          -0.37 ± 0.16   0.0247 
Endotoxin x Baseline CAL 0.42 ± 0.13   0.0009 
† For Categorical variable Clinical Center, values are LSmeans ± SE.  
 ⃰ Negative values of β indicates Clinical attachment loss. 
  R-squared value is 0.41 
 
 
Table 3: Multivariate regression analyses for Gain in Clinical attachment Level 
without Clinical Center 
Variables          Adjusted β ± SE* P value 
Race††   
   Black 0.18 ± 0.03 <0.0001 
   Native American 0.43 ± 0.04 <0.0001 
   White 0.28 ± 0.04 <0.0001 
Baseline PD 0.23 ± 0.08   0.0055 
Baseline PI score           -0.14 ± 0.05   0.0032 
Endotoxin 
Anti-P. intermedia antibodies 
-0.22 ± 0.09 
-0.17 ± 0.11 
  0.0138 
  0.1049 
Baseline PI x Black 0.31 ± 0.07 <0.0001 
Baseline PD x Native American 0.62 ± 0.08 <0.0001 
Baseline PD x White 0.23 ± 0.08   0.0055 
Baseline CAL x Anti-P. intermedia antibodies 0.12 ± 0.04   0.0039 
††For Categorical variable Race, values are LSmeans ± SE. 
 ⃰ Negative values of β indicates loss in clinical attachment level. 
  R-squared value is 0.42 
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Tables 4 and 5 shows the results for Decreased BOP with and without clinical center in 
the multiple regression model. When clinical center was included in the model (Table 4), 
participants from KY clinical center showed a greater decreased BOP similar to the effect 
observed with gain in CAL. Interaction of CRP and baseline PI score was seen as well 
indicating a 1.4% decrease in sites with BOP for each one unit increase in CRP when 
baseline PI score was at average (1.24) in this population. However, if baseline PI score 
was one standard deviation larger (i.e. 1.74), a 1.9% increase in sites with BOP was 
noted. When clinical center was excluded from the multiple regression model (Table 5), 
participant’s education level was found to be significantly associated with decreased 
BOP. Also, among Black participants, about 6% increase in sites with BOP was noted 
when PGE2 levels were at average levels (311 pg/ml). 
 
Table 4: Multivariate regression analyses for Decreased Bleeding on Probing (BOP) 
including Clinical Center 
Variables          Adjusted β ± SE* P value 
Clinical Center ‡   
    MN 27.67 ± 1.54 <0.0001 
    KY 33.83 ± 1.62 <0.0001 
    MS 11.89 ± 1.72 <0.0001 
    NY 
Baseline PI score 
                  21.70 ± 2.03  
                    4.84 ± 3.58 
<0.0001 
   0.1781 
Anti-P. intermedia antibodies                  -29.74 ± 5.99 <0.0001 
CRP                     9.60 ± 3.01   0.0247 
CRP x Baseline PI                    -6.60 ± 2.05   0.0014 
‡ For Categorical Variable Clinical Center, values are LSmeans ± SE.  
 ⃰ Negative values of β indicates increase in bleeding on probing.  
  R-squared value is 0.35 
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Table 5: Multivariate regression analyses for Decreased Bleeding on Probing (BOP) 
without Clinical Center 
Variables          Adjusted β ± SE* P value 
Education¶   
     ≤ 8 years           23.67 ± 2.02 <0.0001 
     9-12 years           26.72 ± 1.17 <0.0001 
     > 12 years           21.27 ± 1.79 <0.0001 
Race††         
   Black                                                     18.75 ± 2.02 <0.0001 
   Native American           29.38 ± 2.39  <0.0001 
   White 
PGE2 
          25. 44 ± 1.87 
         -21.50 ± 8.12                   
<0.0001 
  0.0646 
Anti-P. intermedia antibodies          -20.10 ± 5.88   0.0007 
PGE2 x Black          -6.34 ± 1.67   0.0002 
PGE2 x White          -3.94 ± 1.87   0.0360 
¶For Categorical Variable Education, Race, values are LSmeans ± SE. 
  ⃰ Negative values of β indicates increase in bleeding on probing. 
   R-squared value is 0.34  
 
Results for Decreased PD are shown in Tables 6 and 7. Interaction of anti-C. rectus 
antibodies and PGE2 levels with clinical center showed a significant association with 
decreased PD. Participants from the MN and NY clinical centers experienced a mean 
increase in PD of 0.30 mm following treatment when anti- C. rectus antibodies were at an 
average level (i.e.5.5 ng-µg/ml). Similarly, participants from the MS clinical center 
experienced 0.17 mm increase in PD when PGE2 levels were at an average level (311.4 
pg/ml). Also, anti- A. actinomycetemcomitans antibodies were associated with a 0.6 mm 
increase in PD when clinical center was excluded (Table 7).  
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Table 6: Multivariate regression analyses for Decreased Probing Depth (PD) 
including Clinical Center  
Variables          Adjusted β ± SE* P value 
Smoking Stat††   
   Smoker 0.27 ± 0.05   0.0005 
   Non-smoker 0.43 ± 0.02   0.0014 
Clinical Center   
    MN                                                       0.55 ± 0.46   0.0900 
    KY 0.81 ± 0.50   0.2300 
    MS 1.02 ±0.48   0.0300 
    NY 
Anti-C. rectus antibodies 
PGE2 
0.45 ± 0.20 
-0.36 ± 0.21 
0.11 ± 0.09 
  0.2400 
  0.0867 
  0.2813 
CRP -0.43 ± 0.13   0.0009 
Anti-C. rectus antibodies x MN -0.30 ± 0.09   0.0017 
Anti-C. rectus antibodies x NY -0.43 ± 0.12   0.0009 
PGE2 x MN 0.08 ± 0.04   0.0404 
PGE2 x MS -0.17 ± 0.04 <0.0001 
††For Categorical Variable Smoking Stat and Clinical Center, values are LSmeans ± SE.  
 ⃰ Negative values of β indicates increase in probing depth. 
  R-squared value is 0.65 
 
 
 
Table 7: Multivariate regression analyses for Decreased Probing Depth (PD) 
without Clinical Center 
Variables          Adjusted β ± SE* P value 
Race‡   
   Black  0.28 ± 0.02 <0.0001 
   Native American 0.55 ± 0.03 <0.0001 
   White 0.42 ± 0.03 <0.0001 
Smoking Stat‡   
   Smoker 0.32 ± 0.05 <0.0001 
   Non-smoker 0.41 ± 0.02 <0.0001 
Anti-A. actinomycetemcomitans antibodies           -0.60 ± 0.21   0.0057 
‡ For Categorical Variables Race and Smoking Stat, values are LSmeans ± SE. 
 ⃰ Negative values of β indicates increase in probing depth. 
  R-squared value is 0.63 
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DISCUSSION 
We found that some baseline patient characteristics, periodontal measures and serological 
measures were significant predictors of primary (gain in CAL) and secondary (decrease 
in BOP and decrease in PD) periodontal treatment outcomes after non-surgical 
periodontal treatment in pregnant women with periodontitis. The variables race, baseline 
PD and baseline endotoxin levels were found to be significant predictors for gain in CAL 
with endotoxin levels being negatively associated with the outcome. Overall, Native 
Americans demonstrated a better periodontal treatment response (greater gain in CAL 
and decreased PD) as compared to other races. When clinical center was included in the 
analysis, variables clinical center, baseline PD and baseline endotoxin levels were still 
significant predictors along with baseline CRP levels. We also found significant 
interactions between multiple baseline variables and the primary outcome. Of importance 
are the interactions between baseline PD and Native American and White races in 
relationship with the primary outcome. When adjusted for clinical center, significant 
interactions were seen between baseline PD and antibodies to T. denticola and between 
baseline CRP levels and antibodies to T. denticola in relationship with the primary 
outcome. 
For the secondary outcome decreased PD, variables race, smoking status and antibodies 
to A. actinomycetomcomitans were found to be significant predictors. When adjusted for 
clinical center, variables smoking status and baseline CRP levels were found to be 
significant predictors. For the outcome decreased BOP, variables education and 
antibodies to P. intermedia were significant predictors. When adjusted for clinical center, 
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variables clinical center, antibodies to P. intermedia and baseline CRP levels were found 
to be significant predictors. Overall, the clinical response was less favorable when 
markers of systemic inflammation were highest. 
Participants from the KY clinical center demonstrated the greatest gain in CAL and 
decreased BOP and as compared to other clinical centers. These treatment differences at 
the KY clinical center may be related to the uneven racial distribution of enrolled 
participants among the clinical centers. Most participants from KY were Native 
American who demonstrated a better response to non-surgical periodontal treatment. 
Another explanation would be either intervention or examiner effects or differences in 
study populations that were not captured by included predictors. 
Badersten, et al.24 observed that sites with increased probing depth (>1.0mm) showed an 
improved predictive value (78%) for clinical attachment loss in the long term. They 
concluded that increase in probing depth was most valuable in predicting clinical 
attachment loss. Another study found that in patients with advanced periodontitis 
(residual PD>6 mm) at re-evaluation are at a greater risk to develop sites with additional 
attachment loss than patients with few such residual depths.25 However, both these 
studies had relatively fewer participants (16-49) and could only predict attachment loss in 
patients with greater PD measures. We found a strong positive correlation between PD 
reduction and CAL gain (r=0.78) (Appendix Table 5). This means that the outcomes are 
highly correlated and we're really not looking at three independent assessments of 
periodontal treatment. Additionally, we looked at the relationship between baseline PD 
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and gain in CAL and found that a unit increase in baseline PD was significantly 
associated with gain in CAL at 29-32 weeks follow-up.   
Studies by Tomasi and colleagues26 showed that smoking had a significant negative 
impact, both on the probability of pocket closure and on the magnitude of pocket 
reduction. This finding is also supported in reviews on the effect of smoking on the 
outcome of periodontal treatment.27, 28 However, in our analyses, smoking status was not 
significantly associated with CAL gains and BOP reductions. Furthermore, it was 
significantly associated with decreased PD with non-smokers showing greater decreased 
PD than smokers. We speculate that this might be due to the relatively fewer smokers 
enrolled in our study with significantly different distributions over clinical centers and the 
short term follow-up with them. 
Studies have shown that CRP levels are elevated in periodontitis.29, 30 Additionally, 
Ebersole and colleagues29 observed a relationship between CRP levels and the severity of 
periodontitis. Our findings indicated that unit increase in baseline CRP levels were 
predictive of gain in CAL only when clinical center was included in the regression 
model, indicating possible interaction between CRP levels and clinical center. We found 
a strong negative relationship between endotoxin and gain in CAL after non-surgical 
periodontal treatment. The effect of endotoxin and periodontitis was explained by Daly, 
et al.31 However, we are not aware of any previous studies that explored this relationship. 
Chronic periodontitis is a disease that is initiated by changes in the microbiological 
composition of sub-gingival plaque, and the subsequent alteration of the host immune 
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response. T. denticola has been consistently found associated with progression of 
periodontal disease.32, 33 Studies have also shown T. denticola as being a prognostic 
marker for periodontal treatment.34, 35 In our study, we found significant interactions of 
anti T. denticola antibodies with baseline PD and baseline CRP levels in relationship with 
the gain in CAL. Elevated sub-gingival proportion of A.actinomycetemcomitans, P. 
gingivalis, C. rectus and P. intermedia, together with increased probing depth, 
predisposes adults to increasing risk of recurrent periodontitis.36, 37 In agreement with 
these findings, we also found that antibodies against A.actinomycetemcomitans, C. rectus 
and P. intermedia were associated with smaller reductions in BOP and PD. 
Our study had several strengths and limitations. Our findings are specifically applicable 
to pregnant women with chronic periodontitis, which limits the generalizability of our 
findings to other patient populations. We used full-mouth mean levels of periodontal 
measures instead of site-specific or tooth-specific measures of periodontal treatment 
response. According to D’Aiuto, et al.38 site-specific measures may be the major 
determinant of initial outcomes of treatment in severe periodontitis. Thus, factors that 
predict the clinical treatment response at the tooth (site) level may differ from those that 
predict the response at the patient level.  
We excluded IL-1β, IL-6, IL-8 and TNF-α from current analysis because the majority of 
observations for these analytes (greater than 90 percent) were below their lower limits of 
detection. Therefore, we could not reliably assess the prognostic effects of these serum 
measures. We were unable to find an explanation for the strong negative association of 
endotoxin with gain in CAL after periodontal treatment. Hence, future studies should 
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seek to explore the reason behind this association. We were also unable to determine the 
exact reason for the effect of clinical center on our findings. Finally, non-compliance 
with study treatment may have diluted the findings of our study. 
To our knowledge, our study is the first study to look at prognostic factors of periodontal 
treatment response in pregnant women with periodontitis using a large number of patient 
population. We used data from a previous clinical trial to address the critical question of 
whether baseline patient characteristics, periodontal and serum measures can predict 
periodontal treatment response after non-surgical periodontal therapy in this patient 
population. This may prove helpful for clinicians in the decision-making process 
regarding periodontal as well as restorative treatment planning. This may also enable 
patients to make an informed decision about accepting periodontal treatment 
recommendations. Thus, our study has a definite useful clinical perspective.  
To conclude, we did find a predictive role of certain baseline patient characteristics, 
clinical parameters and serological measures on the response to non-surgical treatment 
(scaling and root planing plus monthly tooth polishing) in pregnant women with chronic 
periodontitis. The findings of the present study suggest that baseline patient 
characteristics such as race; serum measures such as CRP, endotoxins and antibodies to 
T. denticola; and periodontal measures such as PD, play a significant role in predicting 
the gain in CAL after non-surgical periodontal treatment in pregnant women with chronic 
periodontitis. Based on the findings of this study, we can say that clinical response was 
less favorable when some markers of systemic inflammation were highest at baseline. 
Therefore, our study can potentially be helpful to support the development of chair-side 
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test or simple assays where clinicians can do more than just to evaluate clinical 
conditions and look at the other serum markers as prognostic factors. Additional clinical 
investigations may be conducted to corroborate our findings with regards to the clinical 
center effect and to determine the predictive role of endotoxin for gain in CAL. 
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APPENDIX 
 
Table 1: Baseline characteristics of participants by Clinical Center 
Characteristics MN   KY  MS NY P-value 
Age (Yrs) 27 ± 0.5 25 ± 0.54 25 ± 0.56 26 ± 0.59 <0.0001 
BMI 27 ± 0.6 26 ± 0.7 31 ± 0.7 28 ± 0.9   0.0001 
Race - No. (%)      
     Black 25(20) 13(12) 80(83) 72(83) <0.0001 
     Native American 64(52) 65(61) 2(2) 1(1) <0.0001 
     White 41(33) 45(42.4) 17(18) 13(14.9) <0.0001 
Ethnicity - No. (%)      
     Hispanic 89(79) 68(75) 1(1) 12(19) <0.0001 
Education - (%)     <0.0001 
     ≤ 8 years 31.4 23 1 16  
     9-12 years 54 61 53 62  
     > 12 years 15 16 46 22  
Diabetics - (%)                                               2.4 4 9.4 0   0.0073 
Smokers - (%)     8.4 15 20 5   0.0093 
Periodontal measures      
     Tooth sites with bleeding on probing (%) 76 ± 1.4 59 ± 1.6 68 ± 1.6 75 ± 1.7 <0.0001 
     Full-mouth mean probing depth (mm) 3.2 ± 0.05 2.9 ± 0.05 2.7 ± 0.06 2.8 ± 0.06 <0.0001 
     Full-mouth mean clinical attachment level (mm) 1.6 ± 0.05 0.9 ± 0.06 1.9 ± 0.06 1.4 ± 0.06 <0.0001 
     Full-mouth mean plaque index score 1.5 ± 0.04 1.04 ± 0.05 1.27 ± 0.05 1.1 ± 0.05 <0.0001 
Serum measures      
      ¶Anti-A. actinomycetemcomitans antibodies 11 ± 0.7 7 ± 0.8  6.7 ± 0.8 5.9 ± 0.9 <0.0001 
    Anti-C. rectus antibodies 7.2 ± 0.3 5 ± 0.3 4.7 ± 0.3 4.2 ± 0.4 <0.0001 
    Anti-F. nucleatum antibodies 3.5 ± 0.2  3 ± 0.2 3.3 ± 0.2  2.5 ± 0.2   0.0084 
    Anti-P. gingivalis antibodies 28 ± 1.4 14.7 ± 1.5 10.6 ± 1.6 10.2 ± 1.8 <0.0001 
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    Anti-P. intermedia antibodies 7.4 ± 0.3 6.5 ± 0.4 5 ± 0.4 4 ± 0.4 <0.0001 
    Anti-T. denticola antibodies 5.4 ± 0.3 4.5 ± 0.3 5 ± 0.3 3.2 ± 0.3 <0.0001 
    Anti-T. forsythus antibodies 8.9 ± 0.4  6.7 ± 0.5 7.6 ± 0.5 4.9 ± 0.5 <0.0001 
    CRP (ng/ml) 10 ± 0.9 9.4 ± 1 9.5 ± 1.1 8.9 ± 1.2   0.9139 
    PGE2 (pg/ml) 251 ± 28 218 ± 30 367 ± 32 468 ± 35 <0.0001 
    MMP-9 (µg/ml) 0.8 ± 0.04 0.8 ± 0.04 0.7 ± 0.05 0.4 ± 0.05 <0.0001 
    Endotoxin (EU/ml) 1.9 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 2.1 ± 0.1   0.0011 
    Fibrinogen (pg/ml) 16 ± 1 15 ± 1.1 22 ± 1.2 32  ± 1.3 <0.0001 
*± values represent standard deviation. 
¶ the antibody levels to seven periodontal bacteria are expressed as ng or µg/ml of IgG reactivity 
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Table 2: Variables survived in an univariate analyses for Primary outcome i.e. Gain 
in Clinical Attachment Level (p<0.10) 
Variables Unadjusted β ± SE P value 
Race ⃰   
   Black  0.15 ± 0.04   0.0001 
   Native Americans  0.52 ± 0.04 <0.0001 
   White 0.25 ± 0.05 <0.0001 
Ethnicity⃰   
     Hispanic 0.46 ± 0.04 <0.0001 
     Non-Hispanic 0.18 ± 0.03 <0.0001 
Education⃰   
     ≤ 8 years 0.36 ± 0.06 <0.0001 
     9-12 years 0.33 ± 0.04 <0.0001 
     > 12 years 0.20 ± 0.05   0.0001 
Periodontal measures   
     Baseline BOP     0.006 ± 0.001 <0.0001 
     Baseline PD 0.48 ± 0.04 <0.0001 
     Baseline PI 0.14 ± 0.05   0.0051 
Serum measures   
     Anti-A. actinomycetemcomitans antibodies 0.16 ± 0.07   0.0401 
     Anti-P. gingivalis antibodies 0.34 ± 0.06 <0.0001 
     Anti-P. intermedia antibodies 0.31 ± 0.09   0.0014 
     Anti-T. denticola antibodies 0.19 ± 0.09   0.0461 
     Anti-T. forsythus antibodies          0.32 ± 0.10   0.0020 
     CRP 0.12 ± 0.06   0.0391 
     PGE2   -0.14 ± 0.05   0.0073 
     MMP-9 0.16 ± 0.09   0.0764 
     Endotoxin -0.19 ± 0.11   0.0932 
     Fibrinogen -0.45 ± 0.11 <0.0001 
*For categorical variables such as Race, Education and Ethnicity values are LSmeans ± SE  
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Table 3: Variables survived in an univariate analyses for Secondary outcome i.e. 
Decreased Bleeding on Probing (p<0.10) 
Variables Unadjusted β ± 
SE 
P value 
Periodontal measures   
    Baseline CAL -2.66⃰ ± 1.42   0.0610 
    Baseline PD 8.75 ± 1.72 <0.0001 
    Baseline PI 4.33 ± 1.91   0.0240 
Serum measures   
    Anti-A. actinomycetemcomitans antibodies 7.55 ± 2.80   0.0073 
    Anti-C. rectus antibodies 12.36 ± 3.70   0.0009 
    Anti-F. nucleatum antibodies 12.15 ± 4.01   0.0027 
    Anti-P. gingivalis antibodies 11.26 ± 2.20 <0.0001 
    Anti-P. intermedia antibodies 14.63 ± 3.49 <0.0001 
    CRP 5.44 ± 2.13   0.0112 
    PGE2 -6.20
⃰ ± 1.87   0.0010 
    Fibrinogen -9.12⃰ ± 4.14   0.0284 
 ⃰ Negative values of β indicate increase in bleeding on probing 
 
 
 
Table 4: Variables survived in an univariate analyses for Secondary outcome i.e. 
Decreased Probing Depth (p<0.10) 
Variables Unadjusted  
β ± SE 
P value 
Age                                                                    0.01±0.03                              0.0279
Race  ††   
   Black 0.22 ± 0.03   0.0001 
   Native American 0.64 ± 0.04 <0.0001 
    White  0.39 ± 0.04 <0.0001 
Ethnicity ††   
     Hispanic 0.62 ± 0.03 <0.0001 
     Non-Hispanic 0.24 ± 0.03 <0.0001 
Education ††   
     ≤ 8 years 0.50 ± 0.05 <0.0001 
     9-12 years 0.43 ± 0.03 <0.0001 
     > 12 years 0.27 ± 0.05 <0.0001 
Smoking stat ††   
   Smoker 0.26 ± 0.08   0.0005 
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   Non-smoker 0.43 ± 0.02 <0.0001 
Periodontal measures   
    Baseline CAL   0.01 ± 0.001 <0.0001 
    Baseline PD 0.21 ± 0.03 <0.0001 
    Baseline PI 0.25 ± 0.04 <0.0001 
Serum measures   
    Anti-A. actinomycetemcomitans antibodies 0.18 ± 0.07   0.0057 
    Anti-C. rectus antibodies 0.19 ± 0.09   0.0343 
    Anti-P. gingivalis antibodies 0.38 ± 0.05 <0.0001 
    Anti-P. intermedia antibodies 0.35 ± 0.08 <0.0001 
    Anti-T. denticola antibodies 0.23 ± 0.08    0.0063 
    Anti-T. forsythus antibodies 0.34 ± 0.09    0.0002 
    CRP 0.15 ± 0.05    0.0033 
    PGE2 -0.12 
⃰± 0.04    0.0104 
    MMP-9 0.19 ± 0.08    0.0211 
    Fibrinogen -0.37⃰ ± 0.09    0.0020 
††For categorical variables such as Race, Education, Ethnicity and Smoking Stat values are               
LSmeans ± SE.  
 ⃰ Negative values of β indicates increase in probing depth. 
 
 
Table 5: Pearson Correlation (r) between Baseline Periodontal Measures 
 Baseline CAL Baseline PD Baseline BOP Baseline PI 
Baseline CAL 1.0 0.65 0.42 0.40 
Baseline PD 0.65 1.0 0.53 0.50 
Baseline BOP 0.42 0.53 1.0 0.44 
Baseline PI 0.40 0.44 0.50 1.0 
 
 
 
 Table 6: Pearson Correlation (r) between Changes in Periodontal outcomes 
 Gain in CAL Decreased PD Decreased BOP 
Gain in CAL 1.0 0.78 0.33 
Decreased PD 0.78 1.0 0.50 
Decreased BOP 0.33 0.50 1.0 
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Table 7: Serum Biomarkers with low frequency of detection 
 
 
 
Biomarker % of samples below  
lower limit of detection 
IL- 1β 94.3 
IL-6 93.3 
IL-8 96 
TNF- α 93 
